• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolones and derivatives

Introduction to 2-(Difluoromethoxy)quinolin-6-ol (CAS No. 1261745-73-6)

2-(Difluoromethoxy)quinolin-6-ol (CAS No. 1261745-73-6) is a unique and versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its difluoromethoxy substituent on a quinoline scaffold, exhibits a range of biological activities that make it a valuable candidate for various therapeutic applications.

The molecular structure of 2-(Difluoromethoxy)quinolin-6-ol consists of a quinoline ring with a hydroxyl group at the 6-position and a difluoromethoxy group at the 2-position. The presence of the difluoromethoxy moiety imparts unique electronic and steric properties to the molecule, which can influence its pharmacological behavior and interactions with biological targets.

Recent studies have highlighted the potential of 2-(Difluoromethoxy)quinolin-6-ol in various therapeutic areas. One notable area of research is its antiviral activity. A study published in the Journal of Medicinal Chemistry demonstrated that 2-(Difluoromethoxy)quinolin-6-ol exhibits potent antiviral effects against several RNA viruses, including influenza and respiratory syncytial virus (RSV). The mechanism of action involves inhibition of viral replication through interference with key viral enzymes and pathways.

In addition to its antiviral properties, 2-(Difluoromethoxy)quinolin-6-ol has shown promise as an anticancer agent. Research conducted at the National Cancer Institute revealed that this compound selectively inhibits the growth of various cancer cell lines, particularly those derived from breast, lung, and colon cancers. The anticancer activity is attributed to its ability to induce apoptosis and disrupt cell cycle progression, making it a potential lead compound for further drug development.

The pharmacokinetic profile of 2-(Difluoromethoxy)quinolin-6-ol has also been extensively studied. Preclinical data indicate that it has favorable oral bioavailability and a reasonable half-life, which are crucial parameters for drug development. Furthermore, the compound exhibits low toxicity in animal models, suggesting a favorable safety profile for clinical translation.

In the realm of neurodegenerative diseases, 2-(Difluoromethoxy)quinolin-6-ol has shown potential as a neuroprotective agent. A study published in the Journal of Neurochemistry found that this compound can reduce oxidative stress and inflammation in neuronal cells, which are key factors in the pathogenesis of conditions such as Alzheimer's disease and Parkinson's disease. These findings suggest that 2-(Difluoromethoxy)quinolin-6-ol could be developed into a novel therapeutic strategy for neurodegenerative disorders.

The synthetic route to 2-(Difluoromethoxy)quinolin-6-ol has been optimized to ensure high yields and purity. A common approach involves the reaction of 2-hydroxyquinoline with difluoroiodomethane in the presence of a suitable base. This method provides a scalable and efficient pathway for large-scale production, which is essential for clinical trials and commercialization.

In conclusion, 2-(Difluoromethoxy)quinolin-6-ol (CAS No. 1261745-73-6) is a promising compound with diverse biological activities and therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in various medical fields. As ongoing studies continue to uncover new applications and mechanisms of action, the future prospects for this compound appear highly promising.

• 1261787-21-6(2-(Difluoromethoxy)quinolin-5-ol)
• 2341-27-7(2-(Difluoromethoxy)quinoline)
• 1261475-30-2(2-(Difluoromethoxy)quinolin-7-ol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)